Synapse Financial Technologies Inc.'s Chapter 11 bankruptcy has been tossed following unsuccessful efforts to sell its assets. The collapsed financial technology company had no money to support a ...

Build a Plane is an experience on the Roblox platform where you use different blocks to build a plane that you can fly to earn cash that you can use for buying new blocks and upgrades. That said, ...

As the name suggests, Prospecting! is an experience on the Roblox platform where you grab your pan and use your trusty tools to discover rare gems and items that you can sell for in-game currency.

Some online lenders, credit unions and banks offer small personal loans of $1,000 or less to cover urgent expenses. Many, or all, of the products featured on this page are from our advertising ...

We may receive commissions from some links to products on this page. Promotions are subject to availability and retailer terms. But in today's unique economic landscape, where stock market volatility ...

Editorial Note: Talk Android may contain affiliate links on some articles. If you make a purchase through these links, we will earn a commission at no extra cost to you. Learn more. Razer Synapse 4 ...

In 1969, a now-iconic commercial first popped the question, “How many licks does it take to get to the Tootsie Roll center of a Tootsie Pop?” This deceptively simple line in a 30-second script managed ...

The Consumer Financial Protection Bureau has been investigating Synapse Technology's business practices and is preparing to file a complaint against Synapse alleging unfair acts or practices, ...

Day One Biopharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.29, expectations were $-0.35. Operator: Greetings, and welcome to the Day One Biopharmaceuticals Q2 2025 Earnings ...

Greetings, and welcome to the Day One Biopharmaceuticals Q2 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the ...

Management projected full-year 2025 net product revenues of $140 million to $150 million for OJEMDA, citing "strong and persistent demand, deepening prescriber adoption, and consistent payer coverage" ...